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Abstract
Introduction Assessments by the handful of prospective
studies of the association of serum antioxidants and breast
cancer risk have yielded inconsistent results. This multiethnic
nested case-control study sought to examine the association of
plasma carotenoids, retinol, and tocopherols with
postmenopausal breast cancer risk.
Methods From the biospecimen subcohort of the Multiethnic
Cohort Study, 286 incident postmenopausal breast cancer
cases were matched to 535 controls on age, sex, ethnicity,
study location (Hawaii or California), smoking status, date/time
of collection and hours of fasting. We measured prediagnostic
circulating levels of individual carotenoids, retinol, and
tocopherols. Conditional logistic regression was used to
compute odds ratios and 95% confidence intervals.
Results Women with breast cancer tended to have lower levels
of plasma carotenoids and tocopherols than matched controls,
but the differences were not large or statistically significant and
the trends were not monotonic. No association was seen with
retinol. A sensitivity analysis excluding cases diagnosed within 1
year after blood draw did not alter the findings.
Conclusions The lack of significant associations in this
multiethnic population is consistent with previously observed
results from less racially-diverse cohorts and serves as further
evidence against a causal link between plasma micronutrient
concentrations and postmenopausal breast cancer risk.
Introduction
An expert panel recently concluded that an inverse association
of carotenoids with breast cancer risk is possible because of
their antioxidant properties [1], but methodological problems
and the lack of human studies presently limit scientific judg-
ment on the relationship [2]. Assessments of the association
of dietary carotenoids and tocopherols with breast cancer risk
from cohort studies have yielded inconsistent results; and only
a handful of prospective studies have investigated the relation
of risk to serum antioxidants, also with mixed results [3,4]. In
the present nested case-control study, we tested the hypoth-
esis that plasma concentrations of carotenoids, retinol, and
tocopherols are inversely related to breast cancer risk.
Materials and methods
The study population included participants in the biospecimen
subcohort of the Multiethnic Cohort Study [5,6]. Briefly, more
than 215,000 African American, Caucasian, Japanese Ameri-
can, Latino, and Native Hawaiian adults, aged 45 to 75 years
in 1993, completed a 26-page baseline questionnaire
between 1993 and 1996 in Hawaii and in Los Angeles. A
biospecimen subcohort was established among Multiethnic
Cohort Study participants, primarily from 2001 to 2006,
including 36,458 women who completed a short telephone
questionnaire and provided blood (~94% fasting) and over-
night or first-morning urine.
Micronutrient analyses included prediagnostic blood from 334
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linkage with Hawaii and California cancer registries through
2006. Two control individuals for each case were randomly
chosen from the women in the biospecimen subcohort who
were alive and free of breast cancer at the age of the case's
diagnosis, and who matched the case on birth year (± 1 year),
race/ethnicity, location (Hawaii or California), date (± 6
months) and time (± 2 hours) of blood draw, fasting hours (8
to < 10 hours and 10+ hours), and hormone therapy use (cur-
rent versus not current). Plasma concentrations of caroten-
oids, retinoids, and tocopherols were determined by high-
pressure liquid chromatography with photodiode array detec-
tion from our earlier protocol [7,8], with slight modifications
[6]. The median time from blood draw to date of diagnosis was
1 year and 5 months, with the middle 50% of subjects having
follow-up time in the range of 8 months to 2.5 years.
The Multiethnic Cohort Study and the nested case-control
study from the biospecimen subcohort were approved by the
Institutional Review Boards of the University of Hawaii and the
University of Southern California. Cohort participants provided
informed consent for both studies.
Conditional logistic regression, with matched sets as strata,
was used to compute odds ratios and 95% confidence inter-
Table 1
Characteristics of breast cancer cases and controls
General characteristic Cases (n = 286) Controls (n = 535)
Age at blood draw (years)a 66.0 (8.1) 66.0 (8.0)
Fasting hours prior to blood drawa 13.1 (1.9) 13.0 (1.8)
Current hormone therapy usea 99 (35%) 185 (35%)
Ethnicitya
African American 35 (12%) 65 (12%)
Caucasian 59 (21%) 111 (21%)
Japanese American 116 (40%) 213 (40%)
Latina 45 (16%) 86 (16%)
Native Hawaiian 31 (11%) 60 (11%)
High school education or less 97 (34%) 189 (35%)
Body mass index (kg/m2) 25.6 (4.9) 25.4 (5.4)
Nulliparous 35 (12%) 58 (11%)
Number of full-term pregnancies 2.7 (1.8) 2.8 (1.8)
Age at first childbirth 23.8 (4.6) 23.5 (4.5)
Age at menarche 13.0 (1.6) 13.1 (1.6)
Age at natural menopause 49.1 (5.1) 49.5 (4.7)
Smoking status
Never 159 (56%) 334 (63%)
Former 90 (32%) 146 (27%)
Current 35 (12%) 52 (10%)
Pack-years of smoking 6.2 (11.2) 5.4 (11.0)
Mother or sister with breast cancer 31 (11%) 68 (13%)
Alcohol use
Never 170 (60%) 347 (65%)
Ever, below users' median (< 3.4 g/day) 58 (20%) 95 (18%)
Ever, above users' median (> 3.4 g/day) 58 (20%) 93 (17%)
Hours in moderate or vigorous physical activity per day 1.2 (1.3) 1.2 (1.3)
Data presented as mean ± standard deviation or n (%). aMatching variable.Available online http://breast-cancer-research.com/content/11/4/R49
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Table 2
Risk of breast cancer across quartiles of plasma carotenoids, tocopherols, and retinola
Antioxidant (ng/ml) Number of cases/controlsb Odds ratioc 95% confidence interval
Total carotenoids
≤ 1,129.4 76/129 1.00
1,129.5 to 1,510.2 71/135 0.88 0.58 to 1.32
1,510.3 to 1,953.0 73/132 0.90 0.59 to 1.37
≥ 1,953.1 66/139 0.80 0.51 to 1.26
(Ptrend = 0.39)
Total carotenes
≤ 231.7 79/126 1.00
231.8 to 373.5 66/139 0.75 0.49 to 1.14
373.6 to 569.5 82/123 0.99 0.64 to 1.52
≥ 569.6 59/147 0.61 0.38 to 0.97
(Ptrend = 0.08)
α-Carotene
≤ 42.0 73/132 1.00
42.1 to 67.5 70/135 0.95 0.62 to 1.45
67.6 to 101.7 75/131 1.06 0.69 to 1.64
≥ 101.8 68/137 0.88 0.56 to 1.39
(Ptrend = 0.64)
β-Carotene
≤ 180.4 79/127 1.00
180.5 to 301.9 64/140 0.74 0.49 to 1.13
302.0 to 460.8 79/126 0.97 0.63 to 1.48
≥ 460.9 64/142 0.73 0.46 to 1.15
(Ptrend = 0.30)
trans-β-Carotene
≤ 168.8 79/126 1.00
168.9 to 283.7 65/140 0.76 0.50 to 1.14
283.8 to 432.5 76/129 0.91 0.59 to 1.40
≥ 432.6 66/140 0.76 0.49 to 1.19
(Ptrend = 0.37)
cis-β-Carotene
≤ 11.9 78/128 1.00
12.0 to 19.5 72/133 0.89 0.59 to 1.33
19.6 to 30.5 75/129 0.91 0.60 to 1.38
≥ 30.6 61/145 0.68 0.43 to 1.07
(Ptrend = 0.10)
Lycopene
≤ 218.7 73/133 1.00
218.8 to 292.2 75/130 1.04 0.68 to 1.58
292.3 to 391.7 70/135 0.91 0.06 to 1.37
≥ 391.8 68/137 0.88 0.57 to 1.38
(Ptrend = 0.50)Breast Cancer Research    Vol 11 No 4    Epplein et al.
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trans-Lutein/zeaxanthin
≤ 186.8 77/129 1.00
186.9 to 246.5 70/135 0.92 0.60 to 1.41
246.6 to 312.5 70/135 0.91 0.59 to 1.41
≥ 312.6 69/136 0.87 0.57 to 1.34
(Ptrend = 0.55)
trans-Lutein
≤ 129.7 79/126 1.00
129.8 to 174.4 63/143 0.74 0.48 to 1.12
174.5 to 223.4 74/131 0.94 0.62 to 1.44
≥ 223.5 70/135 0.85 0.55 to 1.29
(Ptrend = 0.68)
trans-Zeaxanthin
≤ 53.6 71/134 1.00
53.7 to 70.7 80/126 1.17 0.78 to 1.77
70.8 to 92.2 69/135 0.95 0.60 to 1.50
≥ 92.3 66/140 0.88 0.56 to 1.39
(Ptrend = 0.44)
cis-Lutein/zeaxanthin
≤ 90.8 79/127 1.00
90.9 to 111.7 63/142 0.70 0.46 to 1.06
111.8 to 137.8 77/128 0.90 0.59 to 1.37
≥ 137.9 67/138 0.75 0.48 to 1.16
(Ptrend = 0.37)
trans-Anhydrolutein
≤ 40.0 76/129 1.00
40.1 to 54.0 71/135 0.88 0.57 to 1.36
54.1 to 73.6 74/131 0.94 0.62 to 1.43
≥ 73.7 65/140 0.78 0.50 to 1.22
(Ptrend = 0.31)
cis-Anhydrolutein
≤ 32.9 67/138 1.00
33.0 to 44.5 73/132 1.20 0.78 to 1.84
44.6 to 57.7 73/133 1.21 0.78 to 1.87
≥ 57.8 73/132 1.21 0.77 to 1.91
(Ptrend = 0.47)
α-Cryptoxanthin
≤ 30.8 67/138 1.00
30.9 to 38.9 79/126 1.28 0.84 to 1.96
39.0 to 49.5 71/135 1.10 0.72 to 1.68
≥ 49.6 69/136 1.08 0.68 to 1.70
Table 2 (Continued)
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(Ptrend = 0.96)
trans-β-Cryptoxanthin
≤ 93.8 69/137 1.00
93.9 to 169.0 77/127 1.22 0.81 to 1.85
169.1 to 293.7 61/145 0.85 0.55 to 1.33
≥ 293.8 79/126 1.36 0.85 to 2.16
(Ptrend = 0.30)
cis-β-Cryptoxanthin
≤ 36.4 69/136 1.00
36.5 to 53.9 72/133 1.08 0.71 to 1.64
54.0 to 87.0 67/139 0.96 0.62 to 1.50
≥ 87.1 78/127 1.27 0.81 to 1.99
(Ptrend = 0.28)
Retinol
≤ 842.6 66/139 1.00
842.7 to 997.9 76/130 1.29 0.85 to 1.95
998.0 to 1,187.9 72/133 1.18 0.75 to 1.86
≥ 1,188.0 72/133 1.13 0.73 to 1.76
(Ptrend = 0.73)
Total tocopherols
≤ 14,413.3 78/128 1.00
14,413.4 to 17,909.5 73/132 0.95 0.63 to 1.42
17,909.6 to 23,282.3 63/142 0.74 0.48 to 1.14
≥ 23,282.4 72/133 0.86 0.56 to 1.31
(Ptrend = 0.44)
α-Tocopherol
≤ 11,828.1 80/125 1.00
11,828.2 to 16,021.0 68/138 0.79 0.52 to 1.20
16,021.1 to 21,829.8 66/138 0.75 0.49 to 1.16
≥ 21,829.9 72/134 0.80 0.52 to 1.24
(Ptrend = 0.42)
β + γ-Tocopherol
≤ 619.0 64/142 1.00
619.1 to 1,243.2 71/134 1.24 0.80 to 1.91
1,243.3 to 2,175.2 76/129 1.32 0.87 to 2.02
≥ 2,175.3 75/130 1.40 0.86 to 2.27
(Ptrend = 0.22)
δ-Tocopherol
≤ 190.1 71/134 1.00
190.2 to 257.1 60/145 0.78 0.48 to 1.25
257.2 to 339.2 85/121 1.35 0.82 to 2.22
≥ 339.3 70/135 0.99 0.58 to 1.70
(Ptrend = 0.57)
aLinear dose–response in the logit of risk was tested by a Wald test for each biomarker modeled as a trend variable assigned the median value of 
the appropriate category. bControls (n = 535) were women matched to cases (n = 286) on geographic area, ethnicity, year of birth, date and time 
of specimen collection, fasting status, and hormone therapy use. cAdjusted by conditional logistic regression with matched sets as strata, with 
additional adjustment for age at blood draw and fasting hours prior to blood draw (as continuous variables), as well as body mass index, alcohol 
use, age at menarche, age at menopause, age at first birth, and number of full-term pregnancies.
Table 2 (Continued)
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vals. Biomarker variables were categorized into quartiles
based on the distribution of cases and controls in order to opti-
mize the distribution of cases and controls in each of the strata
of interest so that none of the cells had overly small numbers
of subjects. A trend variable for each biomarker was created
by assigning the median value of the appropriate category.
Aside from matching variables, the full models were adjusted
for the following established breast cancer risk factors [9]:
body mass index, alcohol use, age at first birth, number of full-
term pregnancies, age at menarche, and age at menopause.
Interactions with smoking status, race/ethnicity, and body
mass index were assessed, and a separate model was consid-
ered excluding subjects who were diagnosed within 1 year
after blood draw. All analyses were conducted using SAS soft-
ware (version 9.1; SAS Institute, Cary, NC, USA).
Results
Only matched sets that included one case and at least one
control with no missing data on plasma micronutrients or any
of the adjustment variables were retained in these analyses,
resulting in a study population of 286 cases and 535 controls.
Cases were similar to controls for most baseline characteris-
tics, except that cases were more likely to be former or current
smokers and ever drinkers than controls (Table 1).
Women with breast cancer tended to have lower levels of
plasma carotenoids and tocopherols than matched controls,
but the differences were not large or statistically significant
and the trends were not monotonic (Table 2). When stratified
by smoking status, ever smokers, but not never smokers, in the
highest quartile compared with the lowest quartile of total car-
otenoid levels had a significantly decreased risk of breast can-
cer (odds ratio = 0.29, 95% confidence interval = 0.10 to
0.85 for ever smokers; odds ratio = 1.19, 95% confidence
interval = 0.62 to 2.27 for never smokers). No evidence was
found, however, for an interaction (Pinteraction = 0.17) between
smoking and circulating carotenoids on risk; nor was there evi-
dence that other variables modified the micronutrient-breast
cancer risk association. A sensitivity analysis excluding cases
diagnosed within 1 year after blood draw did not alter the find-
ings.
Discussion
The present case-control study – nested within a large pro-
spective cohort – does not support an association of plasma
carotenoids, retinol, or tocopherols with postmenopausal
breast cancer risk.
The observation of a lack of an association between breast
cancer risk and plasma tocopherols and retinol mirrors what
has been seen in recent prospective studies [4,10-13]. Addi-
tionally, a recent clinical trial did not observe any change in risk
of breast cancer among women assigned to receive vitamin E
supplements [14]. The carotenoid findings, too, are consistent
with the null results from the Shanghai Women's Health Study
[4]. Five other recent large (> 100 cases) prospective studies
of plasma antioxidants and risk of breast cancer, however, did
report some significant associations with carotenoids. Four of
the five studies found breast cancer risk to be inversely asso-
ciated with α-carotene, β-carotene, and/or total carotenoids
[11-13,15]; two of the five studies observed an inverse asso-
ciation with lycopene [10,13], and one of these also observed
an inverse association with γ-tocopherol [13].
The suggested inverse association of carotenoids with breast
cancer risk limited to ever smokers, observed in our study, is
biologically plausible as cigarette smoke contributes to oxida-
tive stress and a reduction in plasma carotenoids [16].
Accordingly, smokers stand to benefit more from the antioxi-
dant properties of carotenoids. Among the two previous stud-
ies that examined the breast cancer-circulating carotenoid
association by smoking status, however, one reported that the
inverse association of α-carotene with breast cancer risk may
be limited to never smokers and past smokers (Pinteraction =
0.10) [12]; the other study found no evidence for a smoking-
circulating carotenoid interaction on breast cancer risk after
restricting the analysis to women who were diagnosed with
breast cancer at least 2 years after blood draw [10]. Two
recent studies of dietary antioxidants and breast cancer risk
from the Collaborative Breast Cancer Study and the Nurses'
Health Study, however, found decreases in risk with increases
in carotenoids among current smokers only, similar to the
present study [17,18].
Limitations to the current study include the use of only one
measure to assess exposure, the possibility that the exposure
was not assessed during the relevant time period, a relatively
short follow-up time, and the inability to stratify by tumor char-
acteristics. These limitations would most probably bias the risk
estimates toward the null. We were also unable to assess
whether the associations we observed with carotenoids were
due to factors other than a high consumption of fruits and veg-
etables that are also related to a healthy lifestyle. We did, how-
ever, adjust for maximum years of education obtained, and saw
no significant changes in the results. The study is strength-
ened by its multiethnic population, which had similarly high lev-
els of antioxidants, including carotenoids, as those reported in
the Nurses' Health Study [12]. These levels are higher than
those reported in the majority of the previous studies
[10,11,13,15]. The difference in antioxidant levels could, how-
ever, be due to laboratory variability and/or due to the diet of
our population.
Conclusions
The lack of significant associations in the present multiethnic
population is consistent with previously observed results from
less racially-diverse cohorts and serves as further evidence
against a causal link between plasma micronutrient concentra-
tions and postmenopausal breast cancer risk.Available online http://breast-cancer-research.com/content/11/4/R49
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